Statistics

Total Visits

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients90

Select a period of time:

Number of views in the range

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients33

Views

Views
October 20253
November 20257
December 20255
January 20264
February 20260
March 202611
April 20263
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States9
Brazil8
Mexico3
United Kingdom2
Argentina2
Angola1
Chile1
Germany1
Algeria1
Ecuador1
 

Top cities views

Views
Los Angeles3
São Paulo2
Buenos Aires2
Ashburn1
Bloomfield1
Brasília1
Campinas1
Cuenca1
Damanhur1
Denver1